Pharmacotherapy 3 Flashcards
Protein kinase inhibitors
Imatinib Erlotinib Sunitinib Everolimus Temisirolimus
Imatinib
Protein kinase inhibitor
GI tumors
CML
Erlotinib
Protein kinase inhibitor
Metastasized NSCLC
Sunitinib
Protein kinase inhibitor
GI tumors
Hepatocellular carcinoma
Clear cell kidney carcinoma
Everolimus
Protein kinase inhibitor, mTOR-inhibitor
mediate- high risk metastatic renal cell cancer
Temisirolimus
Protein kinase inhibitor, mTOR-inhibitor
Low risk metastatic renal cell cancer
Bisphosphonates working
Attach to bone crystals > are absorbed by osteoclasts > induce apoptosis > freeze cycle of bone remodelling
Bisphosphonate medicine
Pamidronic acid
Pamidronic acid
Bisphosphonate
Prevention of osteoporosis
Treatment of hypercalcemia
Metastases and mamma carcinoma
Low risk emesis
Metoclopramide
Dexamethasone
Moderate risk emesis
5HT3-antagonist + dexamethasone
Strong risk emesis
Predose of 5HT3-antagonist + dexamethasone
Then dexamethasone + metoclopramide
Severe risk of emesis + cisplatin
Predose of 5HT3 antagonist + dexamethasone
Then dexametahsone + metoclopramide or aprepitant